Biocytogen Pharmaceuticals (Beijing) First Half 2025 Earnings: EPS: CN¥0.12 (vs CN¥0.13 loss in 1H 2024)

Biocytogen Pharmaceuticals (Beijing) (HKG:2315) First Half 2025 Results

Key Financial Results

• Revenue: CN¥621.0m (up 51% from 1H 2024).
• Net income: CN¥48.0m (up from CN¥50.7m loss in 1H 2024).
• Profit margin: 7.7% (up from net loss in 1H 2024). The move to profitability was driven by higher revenue.
• EPS: CN¥0.12 (up from CN¥0.13 loss in 1H 2024).

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Biocytogen Pharmaceuticals (Beijing) shares are down 9.4% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 1 warning sign for Biocytogen Pharmaceuticals (Beijing) that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.